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We have experienced a time when the majority of trials inves-
tigating novel agents for lupus nephritis (LN) did not reach 
their primary outcomes, despite the pathogenic rationales of 
the trialed agents were solid and preclinical data robust. 
Consequently, these negative results raised methodological 
concerns regarding different aspects of the investigations, 
including enrollment criteria and study population, SLE het-
erogeneity, trial design, and endpoints definition [1].
For years, the design of clinical trials investigating novel 
agents for LN has been based on the paradigm of induction 
and maintenance phases. New agents, including 
Immunosuppressants, were mainly trialed as an add-on to 
induction therapy with the aim to improve renal outcomes 
compared to standard of care when assessed after 6– 
12 months of follow-up. The LUNAR trial confirmed this para-
digm, failing to prove the efficacy of Rituximab in LN, despite 
the promising data in both observational and real-life settings 
[2]. The time has come to finally challenge the concept of the 
systematic need for both induction and maintenance treat-
ment for LN. When the therapy for LN is started, there should 
be a dual aim. On one side, the goal for targeting the inflam-
matory process is limiting kidney injury and to facilitate heal-
ing, as well as reducing the SLE activity to ultimately prevent 
future LN relapses. On the other, minimizing the occurrence of 
adverse effects related to the prolonged use of immunosup-
pression and glucocorticoids should be prioritized. Taking 
these observations into account, novel approaches mainly 
targeting B-cells have recently demonstrated in randomized 
studies to be effective and safe options for the management 
of LN. These approaches have the potential to move forward 
to a more personalized management of patients with LN and 
eventually to challenge the traditional scheme of induction 
and maintenance therapy. Among others, it is worth mention-
ing the BLISS-LN [3] and the NOBILITY trials [4]. These trials 
shared some similarities. Firstly, the therapeutic approaches 
include glucocorticoid and a combination of a conventional 
immunosuppressive (cyclophosphamide, CYC, or mycopheno-
late mofetil, MMF) plus an innovative immunosuppressive 
agent. Secondly, both BLISS-LN and NOBILITY trials incorpo-
rated robust glucocorticoid-tapering plans and investigated 
renal outcomes beyond the typical 12 months (Table 1). The 
success of these trials undoubtedly relies on these methodo-
logical mentioned aspects. However, it should be empathized 
that one peculiarity of these investigations is represented by 
the prolonged use of biological agents as add-on therapy to 
conventual background immunosuppression. With the aim of 
synergistically potentiate the efficacy of Rituximab, while at 
the same time avoiding the conventional maintenance ther-
apy, we previously reported the promising results of a short- 
term intensified B cell depletion protocol (IBCDT) [5,6] in 
patients with severe SLE. IBCDT is a combination of 
Rituximab (RTX), very low doses of CYC (intended to synergize 
the lymphocyte depleting effects of RTX), and methylpredni-
solone pulses (aimed at achieving an immediate anti- 
inflammatory action). This regimen proved to be effective 
and well tolerated in a long-term follow-up, despite the 
absence of any further immunosuppressive therapies. When 
compared to conventional regimens (induction maintenance) 
at 12 months, up to 93% of patients treated with IBCDT 
achieved complete renal response, while 65% and 70% in 
MMF and CYC-based regimens, respectively. The main 
strength of this approach relies on the short time of immuno-
suppression that has been proven to significantly decrease the 
risk of adverse effects associated to the prolonged use of 
a combination of steroids and either MMF or CYC, further 
challenging the paradigm for the need of induction 
maintenance.
1. Expert opinion
Two conceptually novel approaches are arising in the manage-
ment of LN. First, using a biological agent at the same dose 
early and long term has shown successful results in both 
BLISS-LN and NOBILITY trials. Second, a short-term intensified 
B-cell depletion protocol has been proved to control disease 
activity while drastically reducing the total exposure to gluco-
corticoids and immunosuppressants, albeit future randomized 
confirmation is required. These experiences challenge the tra-
ditional scheme of LN treatments and pave the way to com-
bination therapies of LN as a chronic disease. A possible 
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therapeutic approach is detailed in Figure 1 and summarises 
the current therapeutic algorithm in place at our centre.
What have we learned from these trials? The BLISS-LN has 
shown a consistent effect size up to 12% assessed at 1 year 
and sustained over a further 12 month-follow-up. As unique 
for this trial, the effect size was evaluated by Primary Efficacy 
Renal Response and Complete Renal Response (CRR) defini-
tions that were tailored for this study. When compared to 
other LN induction trials, outcome measures of positive 
response include ratio of urinary protein to creatinine of 0.7 
or less and an eGFR drop less than 20%. Critically, BLISS-LN did 
not investigate other endpoints usually considered in LN trials, 
such as the rate of reduction of proteinuria by 50%. While this 
might limit results comparability across studies, one should 
consider BLISS-LN is neither a conventional induction nor 
a maintenance trial. The mechanisms of action of belimumab 
support the concept that this agent may actually exert its full 
Table 1. Main design characteristics of BLISS-LN, NOBILITY, and IBCDT trials.




Efficacy and safety of Belimumab 
in patients with active LN
−18 years of age 
-positive antinuclear 
antibody titers ≥1:80, 
anti–double-stranded 
DNA antibodies, or 
both) 
-Diagnosis of SLE 





-At screening, ratio of 
urinary protein to 
creatinine of 1 or more 
-Biopsy-proven active 
lupus nephritis class III 
or IV with or without 
coexisting class V or 
pure class V LN*.
The primary efficacy renal response is 
defined as a ratio of urinary protein 
to creatinine of 0.7 or less, an eGFR 
that was no worse than 20% below 
the preflare value or at least 60 ml 
per minute per 1.73 m2, and no use 
of rescue therapy for treatment 
failure. 
(primary outcome endpoint: Week 
104)
–Intravenous belimumab or placebo 
on days 1 (baseline), 15, and 29 
and every 28 days thereafter to 
week 100, with final assessments at 
week 104. 
–Standard induction therapy with i. 
v. CYC (500 mg every 2 weeks 
[±3 days] for 6 infusions) or MMF 
(target dose, 3 g per day). In 
patients receiving CYC– 
azathioprine, maintenance therapy 
(target dose, 2 mg per kilogram 
per day; ≤200 mg per day) until 
trial end was initiated 2 weeks after 
the last dose of CYC. 
For MMF induction, maintenance 
therapy consisted of MMF at a dose 
of 1–3 g per day until the end of 
the trial. 
At the investigator’s discretion, 
high-dose glucocorticoids (1–3 
intravenous pulses of 
methylprednisolone [500–1000 mg 
each]) could be administered 
during induction, followed by oral 
prednisone (0.5–1.0 mg per 




A Randomized, Double-Blind, 
Placebo-Controlled, Multi-Center 
Study to Evaluate the Safety and 
Efficacy of Obinutuzumab in 
Patients With ISN/RPS 2003 Class 
III or IV Lupus Nephritis
–Diagnosis of SLE 






lupus nephritis class III 
or IV with or without 
coexisting class V* 
–Proteinuria (urine 
protein to creatinine 
ratio) greater than (>) 
1.0
The endpoint was the percentage of 
patients who reached complete 
renal response, defined as a urinary 
protein-creatinine ratio of 0.5 or 
less, a normal estimated GFR, and 
no active urine sediment. 
(primary outcome endpoint: week 
52)
Two doses of obinutuzumab (1 g 
each) or placebo as add-on to 
glucocorticoids plus MMF Another 
cycle of obinutuzumab was given 
on days 168 and 182
76 weeks
IBCDT Diagnosis of SLE 






lupus nephritis class III 
or IV with or without 
coexisting class V or 
pure class V LN*.
Complete renal response: proteinuria 
<0.5 g/24 hours, normal or near- 
normal estimated glomerular 
filtration rate (within 10% of 
normal estimated glomerular 
filtration rate if previously 
abnormal). 
(primary outcome endpoint: week 
52)
IBCDT: RTX was administered 
intravenously at a dosage of 
375 mg/m2 on days 2, 8, 15, and 
22. Two more doses were 
administered 1 and 2 months 
following the last weekly infusion. 
This treatment was combined with 
2 pulses of 10 mg/kg CYC (reduced, 
if needed, according to renal 
impairment) at days 4 and 17, and 
3 i.v. pulses of 15 mg/kg (days 1, 4, 
and 8) methylprednisolone 
followed by oral prednisone, 50 mg 









* LN based on International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Classification. 
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effect gradually over time and not necessary accelerate a fast 
decrease in proteinuria levels early when belimumab has 
started. With a similar aim, belimumab administration was 
investigated subsequently to rituximab in order to limit BAFF- 
driven early B cells repopulation [7]. One could expect that the 
true added value of belimumab could rely on improving long- 
term outcomes, e.g. by decreasing the rates of disease flares 
and improve the maintenance of a sustained remission. Yet, 
some open questions on the translatability of the results of 
the BLISS-LN trial into clinical practice have been raised [8]. 
From this perspective, one should note that clinical benefit for 
the use of belimumab as add-therapy was mainly observed in 
the subgroup receiving MMF, not for the group who received 
CYC as induction therapy [3]. Secondly, cases showing devel-
opment of active LN during treatment with belimumab in 
patients who did not have a renal phenotype of SLE prior to 
belimumab initiation [9] have been reported. In detail, when 
investigating patients with SLE who received belimumab at 
five European academic practices, Parodis et al. [9] found 6/66 
cases (9.1%) of biopsy-proven de novo LN (4/6 proliferative) 
among the nonrenal belimumab-treated SLE cases after 
a median follow-up of 7.4 months.
All in all, even if overall response rates, especially in in 
certain subset of patients (e.g. patients receiving cyclopho-
sphamide as induction therapy), might have been lower than 
expected, the BLISS-LN trial represents a unique successful 
experience in this space.
Thus, proving the net benefit of an add-on biological ther-
apy, a challenge failed by trials exploring the additional value 
of rituximab, abatacept, and laquinimod [10].
Promising data has been similarly reported by the NOBILITY 
trial, with an observed effect size for CRR assessed at 76 weeks 
and as high as 22%. When compared to the LUNAR trail, one 
should note that glucocorticoids and immunosuppression 
regimen were less aggressive, probably facilitating the 
achievement of primary endpoints; nevertheless, consistent 
with its biological properties, Obinutuzumab seems to have 
a rapid effect of inducing a sustained CD20 + B cells depletion, 
even when compared to other B-cell-depleting monoclonal 
antibodies.
Taken together, both BLISS-LN and NOBILITY suggested 
the prolonged use of biological agents as add-on therapy 
to conventual background immunosuppression, being the 
latest still part of the proposed regimes and continued for 
years once therapy has started. In the last years, a short 
intensive B depletion therapy was shown to be safe and 
effective as the gold standard CYC-based or MMF regimens 
in controlling LN. Initially tested in refractory cases, the 
novelty of IBCDT relies on the rate of CRR (even assessed 
in the long term) despite the lack of an immunosuppressive 
maintenance regimen. IBCDT remarkably moderates the risk 
of adverse effects related to the continued use of 
a combination of glucocorticoids and immunosuppression. 
Additionally, the biological rational of the IBCDT was 
Figure 1. Suggestion of a therapeutic algorithm aiming to a more personalised approach for the management of lupus nephritis. Cyclophosphamide, CYC; 
mycophenolate mofetil, MMF; glucocorticoids, GCs, LN, lupus nephritis.
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confirmed by the observed increase in patients’ Treg num-
ber while maintaining a prolonged B-cell depletion [6,7] 
with a rate of CRR as high as 90% at 1 year with 
a symptom-free life for more than 120 months.
However, some considerations are worth mentioning when 
considering differences in trials designs and therapeutic 
mechanisms of the mentioned schemes. Some limitations in 
the comparability exist when evaluating the results from an 
add-on trial design compared to those observed in trials in 
which different therapeutic schemes are investigated (e.g. 
IBCDT). Critically, the paradigm of induction-maintenance 
therapies seems less applicable to ‘add-on’ trials. Similarly, 
the use of add-on therapies outside the research settings 
should undergo the conventional regulatory approval. 
Finally, Although the LUNAR trial failed to meet the primary 
endpoint, some lessons have been learned from it. In 
a subsequent a post-hoc analysis Gomez Mendez LM and 
coworkers [11] showed that the effect might have been 
dependent on peripheral blood B cell depletion. In line with 
these observations, a combined IBCDT therapy achieved up to 
93% of complete renal response at 12 months while maintain-
ing a prolonged B-cell depletion during the follow-up [6,12]. 
Besides, LUNAR and NOBILITY trial share some similarities, 
including drug dosage scheme and time to assess primary 
outcome (52 weeks). How to move forward and translate 
these experiences into clinical practice? The challenge for the 
future is moving from the concept that one therapeutic 
regime might fit all patients with LN to more tailored, perso-
nalized approaches. Data from studies investigating the use of 
protocolized multiple renal biopsies, along with the availability 
of reliable biomarkers, will help to identify the subset of LN 
patients who might benefit from different therapeutic 
approaches.
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